Exhibit 2
ASSET PURCHASE
AGREEMENT
providing for the
purchase of certain assets of
BAYER DIAGNOSTICS
MANUFACTURING LIMITED
(Seller)
by
KIMBALL ELECTRONICS
(WALES) LIMITED
(Buyer)
CONTENTS
|
1.
|
GENERAL AND LEGAL EFFECT
|
2
|
|
2.
|
SALE AND PURCHASE
|
2
|
|
3.
|
EXCLUDED ASSETS, EXCLUDED LIABILITIES AND
ASSUMED LIABILITIES
|
4
|
|
4.
|
PRICE
|
6
|
|
5.
|
NET BOOK VALUE ADJUSTMENTS AND
APPORTIONMENTS
|
7
|
|
6.
|
MERGER CONTROL FILINGS
|
9
|
|
7.
|
COMPLETION; DELIVERIES AT COMPLETION
|
9
|
|
8.
|
REPRESENTATIONS AND WARRANTIES OF BHC AND
BDML
|
10
|
|
9.
|
LIMITATIONS ON CLAIMS
|
19
|
|
10.
|
REPRESENTATIONS AND WARRANTIES OF KIMBALL AND
KIMBALL WALES
|
22
|
|
11.
|
GENERAL COVENANTS
|
23
|
|
12.
|
EMPLOYEES
|
25
|
|
13.
|
PENSIONS
|
27
|
|
14.
|
VALUE ADDED TAX
|
27
|
|
15.
|
INDEMNIFICATION
|
29
|
|
16.
|
MISCELLANEOUS
|
34
|
|
The following schedules have been omitted from
this filing and will be supplementally furnished to the Securities
and Exchange Commission upon request.
|
|
Schedule 1:
|
Apportionment of initial purchase price
|
|
Schedule 2:
|
Adjustment - description of the process to
value stock (inventory)
|
|
Schedule 3:
|
Listing of employees with knowledge regarding
representations and warranties
|
|
Schedule 4:
|
Transfer
|
|
Schedule 5:
|
Material Transferring Contracts
|
|
Schedule 6:
|
Licenses vested in BDML
|
|
Schedule 7:
|
Employees of BDML on the Completion Date
|
|
Schedule 8:
|
Intentionally left blank
|
|
Schedule 9:
|
Disclosure - general disclosures
|
|
Schedule 10:
|
Product forecast schedule
|
|
Schedule 11:
|
Compromise Agreements
|
1
ASSET PURCHASE
AGREEMENT
1. GENERAL AND LEGAL EFFECT
This Asset Purchase Agreement ( Agreement ), dated as of
the 3rd day of April, 2006, sets forth the terms and conditions on
which (i) Bayer HealthCare LLC ( BHC ), a Delaware limited
liability company, a member of the worldwide group of companies
headed by Bayer AG ( Bayer Group ), desires to cause its
wholly-owned subsidiary Bayer Diagnostics Manufacturing Limited, a
company incorporated in England and Wales with number 403450, (
BDML ) to sell to Kimball Electronics (Wales) Limited, a
company incorporated in England and Wales with number 5675516 (
Kimball Wales ), a wholly owned United Kingdom subsidiary of
Kimball Electronics Manufacturing, Inc., a company incorporated in
the State of Indiana in the United States ( Kimball ), the
manufacturing operation owned and operated by BDML at Bridgend,
Wales, United Kingdom (the Operation ) and accompanying
assets and assign to Kimball Wales certain contracts as more fully
described below, and Kimball desires to cause Kimball Wales to
purchase the Operation and accept such assignment; and (ii) BHC and
Kimball are willing, subject to the completion of the purchase and
sale of the Operation, to enter into a contract manufacturing
agreement, between BHC and Kimball Wales ( Contract
Manufacturing Agreement ) and, in the case of Kimball to cause
Kimball Wales to enter into such Contract Manufacturing Agreement,
under which BHC will contract with Kimball and Kimball Wales for
manufacture and/or packaging of the products currently manufactured
and/or packaged at the Land and Buildings (the Products )
for distribution by the Diagnostics Division and Diabetes Care
Division of BHC or other companies in the Bayer Group (the
Transaction ).
All of the representations, warranties, undertakings and
obligations of BDML and BHC contained in this Agreement are joint
and several. All of the representations, warranties, undertakings
and obligations of Kimball Wales and Kimball contained in this
Agreement are joint and several.
2. SALE AND PURCHASE
BDML shall or shall procure to sell, assign, transfer, and
deliver to Kimball Wales the following assets used in the Operation
as of the Completion Date (defined below) (the Transferring
Assets ):
2
(a) all plant, machinery and equipment,
including spare parts, owned by BDML at Completion (as defined
below) and situated either at the Land and Buildings or at the
locations specified in the Disclosure Schedule (excluding all
fixtures and equipment that are transferred pursuant to the
Transfer) (the Transferring Equipment);
(b) all good and usable inventory and
stocks of raw materials, work-in-progress, finished goods, and
consumables owned by BDML and held at the Land and Buildings or
locations specified in the Disclosure Schedule or in transit to
BDML from suppliers at the Completion Date and that are
commensurate with needs for forecasted Product volumes for the
purposes of manufacturing and/or packaging the Products (the
Stock );
(c) all of BDML's right, title, interest
and benefit subject to the burden of contracts of BDML relating to
the conduct of the Operation and production of the Products,
including all operating and finance leases and all agreements for
purchase by BDML of services and supplies for the Operation
(including, without limitation, any security or similar deposits
relating to such contracts but excluding any contracts of
employment or insurance except the Bayer UK Group Long Term
Disability Policy (number G10246) which Assicurazioni Generali
S.p.A in relation to two Employees and the Group Income Continuance
Plan (number 702886) with Friends Provident in relation to two
Employees (collectively, the Transferring Contracts , of
which the Material Transferring Contracts are listed in the
attached Schedule 5;
(d) to the extent permitted by their
terms or applicable law, all licenses, permits, authorizations and
registrations which are vested in BDML necessary to conduct the
Operation (excluding any licenses, permits, authorizations and
registrations relating to the marketing of the Products) as listed
in Schedule 6 (the Licences );
(e) all records (excluding, unless
otherwise provided for in this Agreement, any tax records),
manuals, maintenance procedures, equipment lists, reports, data,
correspondence, equipment literature, files, and other documents
relating solely to the Transferring Assets and the Employees;
(f) to the extent BDML is able to assign
the benefit of the same, and subject to the burden, all product and
service warranties of manufacturers (other than BDML or BHC)
relating to the Transferring Assets or to the Products manufactured
at the Land and Buildings on or after the Completion Date (the
Manufacturer Warranties ); and
3
(g) subject to clause 2(f), all claims,
causes, or rights of action under the Manufacturer Warranties,
except to the extent relating to items incorporated in Products
sold by BDML prior to the Completion Date.
In addition, BDML will provide Kimball Wales with copies of all
records relating to Product manufacturing, quality warranty and US
Food and Drug Administration ( FDA ) matters (but
specifically excluding any Product design and marketing
documentation) and the right to use the same in connection with the
Contract Manufacturing Agreement.
3. EXCLUDED ASSETS, EXCLUDED
LIABILITIES AND ASSUMED LIABILITIES
3.1 Excluded Assets . Subject to
the Transferring Assets described in clause 2 hereof, the following
assets shall be excluded from the sale that is the subject matter
of this Agreement:
(a) the Land and Buildings which shall
be transferred pursuant to the Transfer to Robert Hitchins Limited
(the Developer );
(b) all intellectual property rights,
including those relating to the Products and the processes for
production thereof, which, together with any improvements thereto,
are and shall remain the sole property of BDML or BHC (as
appropriate) and the parties acknowledge and agree that all matters
concerning intellectual property are addressed exclusively in the
Contract Manufacturing Agreement except that certain licences to
intellectual property rights granted by third parties pursuant to
the Material Transferring Contracts listed in the attached Schedule
5 shall be included in the Transferring Assets and except that BHC
and BDML give the warranty set forth in clause 8.20 hereof;
(c) all contractual arrangements (which
for the avoidance of doubt shall include all contractual
arrangements for the sale or distribution of Products) other than
the Transferring Contracts;
(d) all accounts receivable owing to
BDML, whether due or existing before, at or after the Completion
Date;
(e) all cash in hand and at bank at the
Completion Date; and
(f) all other assets not specifically
included in clause 2 above.
4
3.2 Excluded Liabilities . Except
for the Assumed Liabilities, Kimball Wales shall not assume or be
obligated to pay, perform, or discharge any liability, obligation,
debt, charge, or expense of BHC or BDML of any kind, description,
or character, whether accrued, absolute, contingent, or otherwise,
or whether or not disclosed to Kimball and/or Kimball Wales in this
Agreement, the Disclosure Schedule (defined below) or otherwise,
which is outstanding on, accrued or referable to the period up to
the Completion Date in relation to the Operation, (collectively,
the " Excluded Liabilities "). Without limiting the
generality of the foregoing, and subject to anything to the
contrary contained in this Agreement, and the Assumed Liabilities,
Kimball Wales shall not assume or be obligated to pay, perform, or
discharge any liability, obligation, debt, charge, or expense of
BDML or BHC, and BDML or BHC, as applicable, shall remain
unconditionally liable for, the following:
(a) any liability related to income,
payroll, withholding, sales or any other tax related to the
Transferring Assets or the conduct of the Operation relating to the
period up to the Completion Date, including, but not limited to,
any interest or penalties related thereto (other than bonus
payments payable to the Employees for the period 01 January 2006 to
31 December 2006);
(b) any liability relating to
indebtedness of BDML or the Operation or to the Employees (who by
way of example and without limitation, may manufacture, service,
market, sell, handle, ship, clean, maintain, administer, manage or
otherwise perform activities relating to the Transferring Assets)
relating to the period up to the Completion Date (other than bonus
payments payable to the Employees for the period 01 January 2006 to
31 December 2006);
(c) any liability relating to any
disease, illness, or injury (whether occurring before or after the
Completion Date) that arises out of or results from any act,
omission or occurrence related to the conduct of the Operation
prior to the Completion Date, including any liability for products
liability claims (whether arising before or after the Completion
Date) for goods or services sold and/or delivered before the
Completion Date, except to the extent that such liability arises
out of, or results from, or is increased by any act or omission of
Kimball and/or Kimball Wales after the Completion Date;
(d) any liability (including, but not
limited to, any liability arising from any implied warranty or
breach thereof) caused by BDML and relating to the Transferring
Assets or the conduct of the Operation arising prior to the
Completion Date, including,
5
without limitation, for services performed or, goods
manufactured directly or indirectly, sold, or distributed by the
BDML prior to the Completion Date; and
(e) any liability related to any
violation of any law, statute, rule or regulation that arises out
of or results from any act, omission or occurrence related to any
part of the conduct of the Operation and/or the Transferring Assets
prior to the Completion Date, including, but not limited to, any
claims arising from or in connection with any employment
relationship, such as claims for wrongful dismissal, breach of
employment contracts, sexual harassment or racial or gender
discrimination, defamation or libel, personal injury claims, and
any claims arising under any governing law or regulation relevant
to the employment relationship, except any such liability that
arises out of, or results from, or is increased by any act or
omission of Kimball and/or Kimball Wales after the Completion Date
or with respect to which Kimball Wales is obliged to indemnify BDML
pursuant to clause 15.2.2 of this Agreement; and
3.3 Assumed Liabilities . At the
Completion, Kimball Wales shall assume and agree to pay, perform,
and discharge, when due, the liabilities and obligations of BDML
arising on or after the Completion Date under the
Transferring Contractsand, for the avoidance of doubt, all
liabilities and obligations arising out of carrying on the
Operation and/or the Transferring Assets on or after the Completion
Date and all taxes and national insurance contributions and all
other liabilities and obligations due to and in respect of the
Employees on account of their employment by Kimball Wales on or
after the Completion Date (collectively, the " Assumed
Liabilities ").
3.4 Nothing in this Agreement shall
grant to Kimball and/or Kimball Wales any right, title or interest
in the Land and Buildings (which is to be transferred to a third
party on the date of this Agreement under the terms of the
Transfer). For the avoidance of doubt, none of the representations,
warranties (apart from warranty 8.21) or indemnities given by BDML
and/or BHC under this Agreement are given, made or apply to the
Land and Buildings or to BDML's and/or BHC's ownership, use or
occupation of the Land and Buildings whether in respect of matters
relating to the environment or otherwise.
4. PRICE
4.1 The price for the Transferring
Assets and BDML's and BHC's other covenants in this Agreement,
subject to adjustment as described in paragraph 5 below, will be
GBP 14.4
6
million (the Price ) which shall be apportioned as set
out in Schedule 1 and will be payable as follows: GBP 11.4
million (the "Completion Amount").in cash on Completion and GBP 3.0
million in respect of the Japanese Stock (the "Japanese Amount") in
accordance with clause 4.2.
The Price is exclusive of value added tax if any is chargeable.
In the event value added tax on any of the Transferring Assets is
chargeable, Kimball and/or Kimball Wales shall, pursuant to clause
14, pay such tax.
4.2 The Japanese Amount will be payable
by Kimball Wales to BDML in cash on a shipment by shipment basis
within one hundred five (105) days of shipment in the case of ocean
shipments or within seventy-five (75) days of shipment in the case
of air shipments.
4.3 In the event that there is any
adjustment to the Price under clause 5 of this Agreement, the
apportionment for the Transferring Equipment and for the Stock
shall instead equal their respective values on the Completion
Statement or the Final Completion Statement (if applicable).
4.4 Any payment made by BDML in respect
of a breach of any of the Warranties or any other payment made by
BDML pursuant to this Agreement shall (and shall be deemed to)
reduce the Price paid for the Transferring Assets under this
Agreement by the same amount. The reduction will be allocated as
nearly as possible to the Transferring Assets to which such breach
or payment related or (if that is not possible) as BDML shall
decide.
5. NET BOOK VALUE ADJUSTMENTS
AND APPORTIONMENTS
5.1 The Price shall be adjusted within a
reasonable period (not to exceed 120 days) following Completion as
follows:
(a) if the aggregate net book value of the Land and Buildings,
Transferring Equipment and Stock exceeds GBP 19.7 million, by
adding the excess;
(b) if the aggregate net book value of the Land and Buildings,
Transferring Equipment and Stock is less than GBP 19.7 million, by
deducting the shortfall;
as shown in a completion statement as at 31 March 2006 (the
Completion Statement ) to be prepared by BDML (using the
same accounting policies as those employed in BDML's latest audited
accounts, and following a stock-take carried out in accordance with
the provisions of Schedule 2 by BDML) and which Completion
Statement is to be delivered by BDML to
7
Kimball Wales within 60 days of the Completion Date. Kimball
Wales shall review such Completion Statement within 30 days of
receipt by Kimball Wales of such Completion Statement.
If Kimball Wales notifies BDML in writing pursuant to clause
16.4 of its objections to the Completion Statement proposed by BDML
within 30 days of receipt by Kimball Wales of the Completion
Statement and the parties have not reached agreement within fifteen
(15) days after BDML's receipt of that notice from Kimball Wales, a
further Completion Statement will be prepared by an internationally
recognized accounting firm selected by Kimball Wales and
satisfactory to BDML (acting reasonably) (the " Final Completion
Statement "). Such accounting firm shall be independent of both
Kimball Wales and BDML. The determination by the Final Completion
Statement independent accounting firm shall (save in the case of
manifest error) be final and binding on the parties. The
independent accounting firm will determine which party will bear
the fees and expenses incurred in preparing the Final Completion
Statement, including whether such fees and expenses are to be
shared by the parties and, if so, in what proportions.
5.2 Within fifteen (15) Business Days of
the Completion Statement being agreed or finally determined in
accordance with clause 5.1:
(a) if there is an excess Kimball Wales
shall pay the amount of such excess to such bank account as BDML
shall notify Kimball Wales; and
(b) if there is a shortfall BDML shall
pay the amount of such shortfall to such bank account as Kimball
Wales shall notify BDML.
5.3 Notwithstanding the provisions of
clauses 3 or 15, all items of receipt and expenditure, prepayments
and accruals, periodical charges and outgoings will be apportioned
based on the financial statements of BDML as at 31 March 2006
(except those relating to Excluded Liabilities incurred after 31
March 2006 but prior to Completion that are unusual or
unanticipated by Kimball Wales or relating to Excluded Assets) and
will be paid to or by BDML or BHC as appropriate within 90 days of
Completion. Expected expenses to be so apportioned include, but are
not limited to, depreciation, payroll and benefits, utilities and
service contracts.
8
6. MERGER CONTROL
FILINGS
6.1 Notwithstanding any other provisions
of this Agreement the parties acknowledge and agree that no
representations and/or Warranties are given in relation to Merger
Control Filings.
7. COMPLETION; DELIVERIES
AT COMPLETION
7.1 Place and Date of Completion. The
completion of the purchase and sale contemplated by this Agreement
(the Completion ) shall take place immediately following
execution of this Agreement at the Land and Buildings on or before
3 April, 2006, or at such other place or date as the parties may
mutually agree (the Completion Date ) provided that all the
obligations of the parties set out in this clause 7 have been
discharged.
7.2 Deliveries at Completion.
7.2.1 Kimball Wales's Deliveries
. At the Completion, Kimball Wales shall sign and/or deliver, or
cause to be signed and/or delivered: (a) the Completion Amount; (b)
written instruments or agreements, reasonably acceptable to BDML,
that provide for Kimball Wales's assumption of the Assumed
Liabilities; (c) this Agreement and the Transaction Agreements duly
executed by Kimball Wales and Kimball (as appropriate); (d) a copy
of the Licence relating to the Land and Buildings duly executed by
Kimball Wales and the Developer; (e) a copy of the Transfer duly
executed by the Developer, (f) the purchase price payable to BDML
under the Transfer; (g) any and all other agreements, certificates,
instruments, and other documents required of Kimball Wales and
Kimball under this Agreement (duly executed by Kimball Wales and
Kimball (as appropriate); (h) evidence of the approval of the
Transaction, entry into this Agreement and entry into the
Transaction Agreements by the boards of Kimball and Kimball
Wales.
7.2.2 BDML's Deliveries . At the
Completion, BDML shall sign and/or deliver, or cause to be signed
and/or delivered: (a) assignments, and other instruments of
conveyance that shall be sufficient to transfer title to the
Transferring Assets to Kimball Wales free and clear of all Security
Interests (defined in clause 8.7 hereof); (b) a copy of the
Transfer duly executed by BDML; (c) all such third party consents
as identified in section 8.4 of the Disclosure Schedule hereto as
being obtained prior to Completion; (d) duly executed agreements in
the agreed form for the assignment or novation of Transferring
Contracts; (e) this Agreement and the Transaction Agreements
duly
9
executed by BDML ,BHC, Bayer Plc and Bayer Diagnostics Europe
Limited as appropriate; (f) certified copies of resolutions of
BDML's and BHC's directors, authorizing the consummation of the
transactions contemplated by this Agreement; (g) all records and
other documents included in the Transferring Assets; (h) copies of
all records relating to Product manufacturing, quality warranty and
FDA matters (but specifically excluding any Product design and
marketing documentation); (i) evidence that each Security Interest
(if any) encumbering any of the Assets has been released and
terminated; and (j) any and all other agreements, certificates,
instruments, and other documents required of BDML and BHC under
this Agreement.
8. REPRESENTATIONS AND
WARRANTIES OF BHC AND BDML
8.1 BHC and BDML represent and warrant
to Kimball Wales that each warranty set out in clauses 8.3 to 8.21
inclusive (each a Warranty and together the
Warranties ) is true and accurate in all material respects
at the date of this Agreement. In this Agreement any references to
the knowledge or awareness of BDML is deemed to include the actual
knowledge only of the individuals specified in Schedule 3having
made all reasonable enquiries.
8.2 Disclosure Schedule . BDML
shall deliver to Kimball Wales, on the date of this Agreement,
individually numbered schedules (collectively, the "Disclosure
Schedule") corresponding to the sections and subsections of this
clause. The Disclosure Schedule shall contain exceptions to the
specifically identified section and subsection contained in this
clause, which shall modify such section or subsection, and shall
set forth each exception in reasonable detail, with attached
documentation as necessary to reasonably explain the exception.
BDML shall provide Kimball Wales, on or before the Agreement Date,
with copies of all documents attached to, or referred to in, the
Disclosure Schedule. The Warranties are qualified by the facts and
circumstances fairly disclosed in the Disclosure Schedule. All of
the disclosures set out in the Disclosure Schedule shall have
effect in relation to each of the Warranties and Kimball Wales
shall not be able to claim that any fact or matter has not been
disclosed to it by reason of the relevant disclosure not being
related to any one or more of the Warranties provided such
disclosures fairly and reasonably describe such fact or matter.
8.3 BDML's Organization and Good
Standing . BDML is a limited company duly organized and validly
existing under the laws of the jurisdiction of BDML's formation.
BDML has all requisite corporate power and authority to own the
Transferring Assets and to carry on the Operation as conducted at
the date of this Agreement. So far as BDML is aware, no action
is
10
being taken by the Registrar of Companies in England and Wales
to strike BDML off the register of companies maintained by the
Registrar of Companies in England and Wales. No receiver,
administrative receiver, judicially appointed manager or
administrator has been appointed, nor any notice given, petition
presented or order made for the appointment of any such person,
over the whole or any part of the assets or undertaking of BDML. No
petition has been presented, no order has been made and no
resolution has been passed for the winding up of BDML or for the
appointment of a liquidator or provisional liquidator of BDML. No
voluntary arrangement has been proposed or is in force under
Section 1 of the Insolvency Act 1986 in respect of BDML. No
unsatisfied judgment is outstanding against BDML and no demand has
been served on BDML under Section 123(1)(a) of the Insolvency Act
1986. BDML conducts the operation in offices or places of business,
and the Transferring Assets are located, only at the locations
listed in the Disclosure Schedule, except in the case of Stock in
transit to BDML from the suppliers thereof.
8.4 Enforceability . Each of BDML
and BHC has full corporate power and authority to execute and
deliver this Agreement and the Transaction Agreements, and to
perform its respective obligations hereunder and thereunder, and
each of such agreements constitutes the legally enforceable
obligation of BDML and/or BHC, as the case may be. As far as BDML
is aware, neither BDML nor BHC is required to give any notice to,
make any filing with, or obtain any authorization, consent, or
approval of any government or governmental agency or third party in
order for the transactions contemplated by this Agreement or the
other Transaction Agreements to be consummated except as disclosed
at section 8.4 of the Disclosure Schedule, and, except as so
disclosed, all such notices, filings, authorizations, consents and
approvals have been given, made or obtained, as applicable, before
the Completion Date.
8.5 No Conflict with Other
Instruments or Proceedings . The signing and delivery of this
Agreement and the Transaction Agreements and the consummation of
the transactions contemplated hereby and thereby will not (a)
result in the breach of any of the terms or conditions of, or
constitute a default under, BDML's memorandum and articles of
association or BHC's corporate charter or bylaws or any contract,
agreement, lease, commitment, indenture, mortgage, pledge, note,
bond, license, or other instrument or obligation to which BDML or
BHC is a party or by which BDML or BHC may be bound or any of the
Transferring Assets may be materially and adversely affected; (b)
as far as BDML is aware (following all reasonable inquiries),
violate any law, rule, or regulation of any administrative agency
or governmental body in England and Wales or the European Union or,
as far as BDML is aware, violate any order, writ, injunction, or
decree of any court, administrative
11
agency, or governmental body in England and Wales or the
European Union; (c) result in the imposition of any lien or
encumbrance on any of the Transferring Assets; or (d) give rise to
any right of first refusal or similar right to any third party with
respect to any interest in any of the Transferring Assets.
8.6 Compliance with Laws and Other
Regulations .
(i) For the three (3) years prior to the
date of this Agreement as far as BDML is aware with respect to the
Operation, the Employees, and the Transferring Assets BDML has, in
all material respects, complied with all requirements of local law,
rule and regulation (including those relating to taxes) and all
requirements of any governmental body or agency of England and
Wales with respect to the conduct of the Operation, or the
Employees, or the Transferring Assets; and
(ii) there is no actual and, as far as
BDML is aware, no written pending or written threatened action,
suit, proceeding, hearing, investigation, charge, complaint, claim
or demand against BDML or any of the Transferring Assets or
relating to the Operation alleging any failure to so comply.
8.7 Title; Encumbrances . The
Transferring Assets are free and clear of all claims, liens,
mortgages, security interests, pledges, encumbrances, charges,
obligations, and other restrictions, except for restrictions solely
arising from and relating to the Assumed Liabilities (collectively,
the Security Interests ). BDML has good and marketable title
to all of the Transferring Assets. There is no actual nor, so far
as BDML is aware, any pending or threatened dispute or claim made
by any other person or entity concerning any such title to or
ownership of any of the Transferring Assets or, except as disclosed
in section 8.7 of the Disclosure Schedule, any Security
Interest in any of the Transferring Assets. Except as disclosed in
Section 8.7 of the Disclosure Schedule, the Transferring Assets
together with the fixtures deemed to be part of the Land and
Buildings that are transferred pursuant to the Transfer, equipment
owned by Bayer PLC to be used by Bayer PLC to provide services
under the Transitional Services Agreement or to be made available
to Kimball Wales under the Parts Distribution Agreement include all
the machinery and tooling necessary for the conduct of the
Operation in all material respects in the same manner as the
Operation is being conducted as at Completion.
8.8 Absence of Certain Changes or
Events . Since the Last Accounting Date, as defined in clause
16.14 hereof, there has been no material adverse change in the
condition of the Transferring
12
Assets, the Operation or the conduct of the Operation as of the
Completion Date, financial or otherwise, except as set forth in
section 8.8 of the Disclosure Schedule. So far as BDML is aware,
since the last forecast (attached hereto as Schedule 10) for
purchase of Products, no event has taken place that BDML reasonably
expects will cause the forecast to change in any material
respect.
8.9 Suppliers . Since the Last
Accounting Date, and except as set forth in section 8.9 of the
Disclosure Schedule, there has not been any adverse change in the
terms on which BDML contracts with BDML's 20 largest suppliers and
BDML's 10 largest service providers (in terms of BDML's annual
spend in connection with the Operation), whose names are listed in
section 8.9 of the Disclosure Schedule. None of the suppliers or
service providers listed in section 8.9 of the Disclosure Schedule
has indicated to BDML that it wishes to make a material adverse
change to the terms on which it contracts with BDML or, as far as
BDML is aware, no such supplier or service provider has filed or
intends to pursue a claim in excess of GBP 10,000 for nonpayment or
nonperformance by BDML.
8.10 Stock . All Stock is of a
good and merchantable quality, or is suitable and usable for the
manufacture of Products. None of the Stock is obsolete or in excess
of the necessary requirements of the conduct of the Operation
commensurate with needs for BDML's forecasted Product volumes. None
of the Stock related to urine strip Products shall decay or degrade
or become less merchantable, by virtue of normal and customary
storage as is currently in place at the Operation prior to such
time as such materials could reasonably be expected to be used in
accordance with BDML's forecasted Product volumes.
8.11 Location and Condition of
Machinery and Equipment . Except as set forth in the Disclosure
Schedule all plant, machinery and equipment (including spare parts)
comprised in the Transferring Assets will be located at the Land
and Buildings on the Completion Date. The plant, machinery and
equipment comprised in the Transferring Assets are in good
operating condition and good maintenance and repair (ordinary wear
and tear excepted and consistent with their age), for the purposes
for which they are presently being used.
8.12 Transferring Contracts . The
Material Transferring Contracts are listed in Schedule 5. BDML has
provided Kimball Wales with a copy of each Material Transferring
Contract. Except for rights to use of the assets to be transferred
to the Developer pursuant to the Transfer, the Transitional
Services Agreement, the Contract Manufacturing Agreement and the
Parts Distribution Agreement, the Transferring Contracts are all
the contracts, arrangements, and agreements, of whatsoever nature,
necessary to enable Kimball Wales to
13
conduct the Operation in all material respects in the same
manner as the Operation is being conducted as at Completion. The
Transferring Contracts are valid and enforceable in accordance with
their terms, and, BDML and, so far as BDML is aware, all other
parties to each of those Transferring Contracts have performed all
obligations required to be performed in connection with these
Transferring Contracts to date. Neither BDML nor, so far as BDML is
aware, any other party is in default or in arrears under the terms
of these Transferring Contracts, and no condition exists or event
has occurred which, with the giving of notice or the lapse of time
or both, would constitute a default under any of them. No Material
Transferring Contract is out of the ordinary and usual course of
business. BDML has not given any power of attorney to any person,
firm, or corporation for any purpose whatsoever relating to the
Transferring Assets.
8.13 Litigation . There is no
actual and, as far as BDML is aware, no threatened or pending suit,
action, proceeding (legal, administrative, or otherwise), claim,
investigation, or inquiry (by an administrative agency - including
the FDA, governmental body, or otherwise) by, against, or otherwise
affecting BDML with respect to the conduct of the Operation or any
of the Transferring Assets. There is no outstanding judgment,
order, writ, injunction, or decree of any court, administrative
agency, governmental body, or arbitration tribunal against or
affecting BDML in relation to the conduct of the Operation or any
of the Transferring Assets.
8.14 Product Liabilities . Within
the last 5 years, BDML's costs with respect to product liability or
warranty claims associated with the conduct of the Operation have
not exceeded, on a per annum basis, GBP 20,000 during such
period.
8.15 Permits and Licenses . Save
for any licence, permit or authorization held by or vested in a
contractor who provides services to BDML in connection with the
operation of the Transferring Assets or the conduct of the
Operation, all permits, licenses, orders, and approvals necessary
to own or operate the Transferring Assets in connection with the
conduct of the Operation are identified in Section 8.15 of
the Disclosure Schedule, are assignable to Kimball Wales and are in
full force and effect. The Licences have been complied with by BDML
in all material respects. All fees and charges incident to the
Licences have been fully paid and are current, and, so far as BDML
is aware, no suspension has been threatened or could reasonably be
expected to result by reason of the transactions contemplated by
this Agreement.
8.16 Brokers . BDML has not
retained or employed, and is not and will not be liable to pay, any
broker, finder, investment banker, or other person, or taken any
action, or entered into any
14
agreement or understanding that would give any broker, finder,
investment banker, or other person any valid claim against Kimball
Wales or BDML for a commission, brokerage fee, or other
compensation.
8.17 Intercompany Arrangements .
BDML has not entered into any material contracts, agreements, or
commitments with any of BDML's Affiliates with respect to the
Transferring Assets or the BDML's operations being carried on at
the Operation, except as listed on section 8.17 of the
Disclosure Schedule.
8.18 Accuracy of Statements .
BDML's financial statements dated as of 31 August 2005 and 31
December 2005 (such financial statements being attached to section
8.18 of the Disclosure Schedule) have been prepared from the books
and records of BDML and fairly present the financial position of
BDML as of their respective dates and its results of operations for
the periods ended on such dates. The financial statements of 31
December are prepared in accordance with generally accepted
accounting principles in the United Kingdom. The financial
statements of 31 August are prepared in accordance with IAS, the
only departure from generally accepted accounting principles of the
United Kingdom being the Pension Provision and related Deferred Tax
impact.
8.19 Employment . The only
representations and Warranties given in respect of matters relating
to Employees are in clause 8.6 and this clause 8.19. Except as
otherwise disclosed in the Disclosure Schedule:
(i) [ Note: Intentionally left
blank ];
(ii) since September 19, 2005, no
changes have been made to the terms of employment, benefits or
conditions of service of any Employee or to the terms of any
agreement or arrangement with any trade union, employee
representative or body of employees or their representatives which
may affect the Employees;
(iii) BHC and/or BDML have disclosed in
writing to Kimball and/or Kimball Wales the following, all of which
are true, accurate and complete in all material respects as of the
Completion Date:
(a) copies of all service contracts and
contracts for services, handbooks, policies and other relevant
documents which apply to the Employees;
15
(b) full particulars of the current
terms of employment or engagement and benefits of all Employees
including, without